Kevin Franciotti: Use of Psychedelics in the Treatment of Psychotic Disorders

Psychedelic substances in the treatment of psychosis have a complex history marked by early research into LSD and psilocybin. During the mid-20th century, clinicians attempted to use these compounds as empathy-inducing tools to interact with withdrawn or catatonic patients. Despite initial reports suggesting that LSD could help patients reach a state of emotional openness conducive to therapeutic connection, the subsequent criminalization of these substances led to a long halt in clinical investigation. The presentation chronicles this timeline and highlights the need for a renewed, ethically sound assessment of how such medicines might interact with current standards of care. Modern research shifts toward MDMA as a potential tool in managing psychotic spectrum conditions. Although MDMA is traditionally considered an entactogen rather than a classic psychedelic, its capacity to foster openness and interpersonal trust remains a focal point for researchers exploring how to address negative symptoms like social withdrawal and anhedonia. The conversation explores these historical precedents while emphasizing the inherent safety and ethical risks involved in investigating therapeutic potential among vulnerable populations with chronic mental health diagnoses.